InMed Pharmaceuticals

Edison Investment Research is terminating coverage on InMed Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Equities

Equities by Sector

Sectors

Megatrends

Thematics

Latest

REE industry M&A update

Edison explains: The next phase of the obesity market

Edison explains: The cost of insecure infrastructure

Audiovisual

Latest

Vantage: US investors are pouring billions into non-US stocks – is your company on their radar?

Regional REIT – executive interview

Terrain Minerals – executive interview

About Edison

Corporates

Investors

Careers

InMed Pharmaceuticals (US: INM)

Latest Insights

InMed Pharmaceuticals — THCV launch expands rare cannabinoids portfolio

InMed Pharmaceuticals — Health and wellness product launches

InMed Pharmaceuticals — Notable launches of high-value rare cannabinoids

InMed Pharmaceuticals — Generating commercial sales of CBC and CBT

Market Data

Sector

Webinar: InMed Pharmaceuticals

InMed Pharmaceuticals — NM-755 Phase II about to begin

InMed Pharmaceuticals — Acquiring BayMedica

InMed Pharmaceuticals and BayMedica – executive interview

Webinar: InMed Pharmaceuticals

InMed Pharmaceuticals — Phase II enrolment to begin in second half

InMed Pharmaceuticals – Edison Open House interview

InMed Pharmaceuticals — INM-755 Phase I complete, on to Phase II

Executive interview – InMed’s cannabinol (CBN) formulation for glaucoma

Executive interview – InMed: Leading the way in the therapeutic development of cannabinol (CBN)

InMed Pharmaceuticals — INM-755 trial full enrollment expected this quarter

Executive interview – InMed: A leader in the development of cannabinol (CBN) therapeutics

InMed Pharmaceuticals — Developing cannabinol (CBN)

InMed Pharmaceuticals — CTA filed on schedule

InMed Pharmaceuticals — INM-755 getting closer to the clinic

Executive interview – InMed Pharmaceuticals

InMed Pharmaceuticals — Fiscal Q319 results

InMed Pharmaceuticals — Entering the clinic by the end of the year

InMed Pharmaceuticals — Biosynthesis and INM-750 Progress on Track

InMed Pharmaceuticals — Progressing their programs

InMed Pharmaceuticals — Innovating cannabinoids